A5068846522- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Cancer and Skin Lesions
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- AI in cancer detection
- Cancer Cells and Metastasis
- Advanced Breast Cancer Therapies
- Salivary Gland Tumors Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Music Technology and Sound Studies
- Cancer Diagnosis and Treatment
- Italian Literature and Culture
- Breast Implant and Reconstruction
- Musicology and Musical Analysis
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Sphingolipid Metabolism and Signaling
- Gene expression and cancer classification
- Renal cell carcinoma treatment
- Urologic and reproductive health conditions
- Tumors and Oncological Cases
University of Bari Aldo Moro
2008-2025
European Institute of Oncology
2010-2020
Ripamonti
2009-2020
Istituti di Ricovero e Cura a Carattere Scientifico
2013-2020
Policlinico San Matteo Fondazione
2020
Institute of Cancer Research
2012-2018
Ontario Institute for Cancer Research
2012-2018
Indiana University – Purdue University Indianapolis
2016-2018
Juravinski Hospital
2018
Sinai Health System
2018
In breast cancer, immunohistochemical assessment of proliferation using the marker Ki67 has potential use in both research and clinical management. However, lack consistency across laboratories limited Ki67's value. A working group was assembled to devise a strategy harmonize analysis increase scoring concordance. Toward that goal, we conducted reproducibility study. Eight received 100 cancer cases arranged into 1-mm core tissue microarrays—one set stained by participating laboratory one...
To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women early breast cancer.Breast International Group (BIG) 1-98 randomly assigned 8,010 patients to four arms comparing sequences each agent. The Central Pathology Office received material for 6,549 (82%), which 79% were assessable (6,291 patients). Prognostic predictive value both local central hormone...
Purpose To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy postmenopausal women early breast cancer. Patients Methods Breast International Group (BIG) 1-98 randomly assigned 8,010 patients to four treatment arms Let Tam sequences each agent. Of 4,922 receive 5 years monotherapy either agent, 2,685 had primary tumor material available for central pathology assessment LI by...
Adjuvant chemotherapy decisions in breast cancer are increasingly based on the pathologist's assessment of tumor proliferation. The Swiss Working Group Gyneco- and Breast Pathologists has surveyed inter- intraobserver consistency Ki-67-based proliferative fraction carcinomas.Five pathologists evaluated MIB-1-labeling index (LI) ten carcinomas (G1, G2, G3) by counting eyeballing. In same way, 15 all over Switzerland then assessed MIB-1-LI three G2 carcinomas, self-selected or pre-defined...
To assess whether the risk for nonsentinel node metastases may be predicted, thus sparing a subgroup of patients with breast carcinoma and positive sentinel lymph (SLN) biopsy completion axillary dissection (ALND).The SLN is only involved in majority undergoing ALND biopsy. A model to predict status nodes could help tailor surgical therapy those most likely benefit from ALND.All 1228 were reviewed histologically reclassified according current TNM classification malignant tumors as bearing...
Several small studies have reported that having a high percentage of breast tumor cells express the proliferation antigen Ki-67 (ie, labeling index) predicts better response to neoadjuvant chemotherapy. However, predictive value index for adjuvant chemotherapy is unclear. To investigate whether chemoendocrine therapy, we assessed expression in tissue from 1924 (70%) 2732 patients who were enrolled two randomized International Breast Cancer Study Group trials therapy vs endocrine alone...
OBJECTIVE To compare the early oncological, perioperative and functional outcomes of robotic‐assisted radical prostatectomy (RARP) vs open retropubic RP (RRP) in a laparoscopically naive centre, as robotic assistance aids surgeon minimally invasive prostate surgery, by offering magnification superior dexterity. PATIENTS AND METHODS From 1 November 2006 to 31 December 2007, 120 patients had RARP; this group was followed prospectively evaluated for (measured at 3, 6 12 months after surgery),...
The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 recognized substantial progress in pathological characterization breast cancer subtypes. A useful surrogate definition was developed to distinguish luminal A-like from B-like disease based a combination estrogen receptor (ER), progesterone (PgR) and Ki-67 status, without requirement for molecular diagnostics. Differences depend upon choice threshold value PgR positivity. We aimed verify...
Background: Tumor levels of steroid hormone receptors, a factor used to select adjuvant treatment for early-stage breast cancer, are currently determined with immunohistochemical assays. These assays have discordance 10%–30% previously extraction We assessed the concordance and predictive value receptor status as by on specimens from International Breast Cancer Study Group Trials VIII IX. trials predominantly compared chemoendocrine therapy endocrine alone among pre- postmenopausal patients...
Retrospective studies suggest that primary breast cancers lacking estrogen receptor (ER) and progesterone (PR) not overexpressing human epidermal growth factor 2 (HER2; triple-negative tumors) are particularly sensitive to DNA-damaging chemotherapy with alkylating agents.Patients enrolled in International Breast Cancer Study Group Trials VIII IX node-negative, operable cancer centrally assessed ER, PR, HER2 were included (n = 2,257). The trials compared three or six courses of adjuvant...
Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in breast and other cancers. However, clinical utility immunohistochemical (IHC) assay for immunohistochemistry been hampered by unacceptable between-laboratory analytical variability. The International Working Group conducted a series studies aiming to decrease this variability improve evaluation Ki67. This study tries assess whether acceptable performance can be achieved on prestained core-cut...
The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability hampered its clinical utility. International Breast Cancer Working Group undertaken a systematic programme to determine whether measurement can be analytically validated and standardised among laboratories. This study addresses acceptable scoring reproducibility achieved on excision whole sections.Adjacent sections from...
An altered metabolism is involved in the development of clear cell renal carcinoma (ccRCC). MUC1 overexpression has been found to be associated with advanced disease and poor prognosis. In this study, we evaluated metabolomic profile human ccRCC, according expression, integrated it transcriptomic data. Moreover, analyzed role sustaining ccRCC aggressiveness prognostic value its soluble form CA15-3. Integrated analysis showed that MUC1-expressing was characterized by metabolic reprogramming...
To centrally assess estrogen receptor (ER) and progesterone (PgR) levels by immunohistochemistry investigate their predictive value for benefit of chemo-endocrine compared with endocrine adjuvant therapy alone in two randomized clinical trials node-negative breast cancer.International Breast Cancer Study Group Trial VIII cyclophosphamide, methotrexate, fluorouracil (CMF) chemotherapy 6 cycles followed goserelin either modality pre- perimenopausal patients. IX three CMF tamoxifen 5 years...